Recent Company News

• 12:49 AM ET Apr 18, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 08:58 AM ET Apr 16, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:23 PM ET Apr 16, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 06:49 AM ET Apr 16, 2026
  

  Lilly announces topline results from Phase 3 ACHIEVE-4 trial evaluating Foundayo (orforglipron) compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk ($905.03, 0.00)

• 01:17 AM ET Apr 16, 2026
  

  Roche to initiate Phase III study to expand access to Elevidys, the first approved gene therapy for Duchenne muscular dystrophy (CHF 317.00, 0.00)

• 12:05 PM ET Apr 14, 2026
  

  FDA revokes orphan drug designation for vosoritide in Turner's syndrome ($55.40, +0.52)

• 06:35 PM ET Apr 10, 2026
  

  Follow-up: Hemab Therapeutics files for Nasdaq IPO of indeterminate size

• 06:47 AM ET Apr 09, 2026
  

  Lilly's new oral GLP-1 pill for weight loss, Foundayo, now available in the U.S. ($953.30, 0.00)

• 02:40 AM ET Apr 09, 2026
  

  Chugai Pharmaceutical, Zenyaku terminate co-promotion of Rituxan in Japan, effective 3-Sep (¥8775.0000, 0)